Literature DB >> 22507471

HMB-45 negative clear cell perivascular epithelioid cell tumor of the skin.

Teresa Pusiol1, Doriana Morichetti, Maria Grazia Zorzi, Surace Dario.   

Abstract

The first case of cutaneous clear cell perivascular epithelioid cell tumor (PEComa) with negative HMB-45 marker is presented. The tumor was a nodule 3x2 cm in size, located on the right foot in a 60-year-old man. The lesion consisted of large irregularly shaped cells with clear cytoplasm, negative for S-100 protein, HMB-45, Melan-A, pancytokeratin, epithelial membrane antigen and CAM5.2. Multifocal positivity for desmin, microphthalmia transcription factor and tyrosinase was found. The diagnosis of cutaneous PEComa of clear cell type was made. Clear cell change is a very unusual finding in PEComa and may pose problems in diagnostic differentiation from other clear cell cutaneous lesions that may be excluded with immunohistochemistry. In our case, the HMB-45 negativity may be explained by extensive clear cell change. Additional studies are necessary to accept the clear cell cutaneous HMB-45 negative PEComa as a new variant of perivascular epithelioid cell tumor.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22507471

Source DB:  PubMed          Journal:  Acta Dermatovenerol Croat        ISSN: 1330-027X            Impact factor:   1.256


  3 in total

Review 1.  Cutaneous perivascular epithelioid cell tumors: A review on an infrequent neoplasm.

Authors:  Mar Llamas-Velasco; Luis Requena; Thomas Mentzel
Journal:  World J Methodol       Date:  2016-03-26

2.  Premelanosome-negative inflammatory angiomyolipoma of liver with expression of cathepsin K and TFE3.

Authors:  Ke Sun; Ming Zhao; Hongtian Yao; Lijun Wang; Jianfeng Wei
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

3.  Aberrant intermediate filament and synaptophysin expression is a frequent event in malignant melanoma: an immunohistochemical study of 73 cases.

Authors:  Ryan C Romano; Jodi M Carter; Andrew L Folpe
Journal:  Mod Pathol       Date:  2015-05-29       Impact factor: 7.842

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.